Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

Rhea-AI Summary

Biodesix (Nasdaq: BDSX) announced poster presentations of new clinical and development data at two scientific meetings in December 2025. At NACLC (Dec 5–7, Chicago) the company will present post‑market Nodify Lung® data that address timely lung nodule risk classification and modeling of autoantibody testing impact on time to lung cancer diagnosis. At SABCS (Dec 9–12, San Antonio) Biodesix will present development data for an ultra‑sensitive ESR1 droplet digital PCR test for detecting and monitoring ESR1 variants in HR+/HER2‑ advanced breast cancer; the test is offered to biopharmaceutical customers via Development Services. The company also received two recognitions at ISPOR Europe 2025 for research on pulmonary nodule follow‑up and related healthcare costs, to be published in the December supplement of Value in Health.

News Market Reaction

+3.96%

2 alerts

+3.96% News Effect

+$3M Valuation Impact

$66M Market Cap

0.4x Rel. Volume

On the day this news was published, BDSX gained 3.96%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $66M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

NACLC 2025 dates: December 5–7, 2025 SABCS 2025 dates: December 9–12, 2025 ISPOR Europe 2025: November 2025 +5 more

8 metrics

NACLC 2025 dates December 5–7, 2025 North American Conference on Lung Cancer presentation window

SABCS 2025 dates December 9–12, 2025 San Antonio Breast Cancer Symposium presentation window

ISPOR Europe 2025 November 2025 Timing of cost and outcomes research recognitions

Two-year period 2 years Pulmonary nodule and lung cancer workup cost window in US study

Best Poster Award 1 award Best General Poster Research Presentation at ISPOR Europe 2025

Top 5% certificate Top 5% ISPOR research performance recognition for pulmonary nodule cost study

Poster Session PS4-02-29 SABCS session ID for ultra-sensitive ESR1 ddPCR test poster

Conference supplement December 2025 Value in Health issue publishing ISPOR award-winning research

Market Reality Check

Price: $9.66 Vol: Volume 26,676 vs 20-day a...

low vol

$9.66 Last Close

Volume Volume 26,676 vs 20-day average 66,158 (volume_relative 0.4) shows subdued trading ahead of the meetings. low

Technical Shares at $8.02 are trading below the $8.69 200-day moving average.

Peers on Argus

BDSX fell 2.16% while peers like PRE (+7.8%), XGN (+0.98%), BNR (+0.47%), and FO...

BDSX fell 2.16% while peers like PRE (+7.8%), XGN (+0.98%), BNR (+0.47%), and FONR (+0.52%) were positive and MDXH was flat, indicating stock-specific dynamics rather than a sector-wide move.

Historical Context

5 past events · Latest: Dec 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 03	Scientific conferences	Positive	+4.0%	New Nodify Lung® and ESR1 assay data at major December scientific meetings.
Nov 03	Earnings update	Positive	-7.2%	Q3 2025 revenue growth, higher margins, raised guidance, narrowing net loss.
Oct 30	R&D roadmap	Positive	+0.5%	Corporate Day outlining diagnostic services roadmap and technology partnerships.
Oct 22	Partnership expansion	Positive	-12.2%	Expanded Bio-Rad agreement to develop and validate ddPCR IVD assays.
Oct 20	Earnings preview	Neutral	+3.1%	Scheduling Q3 2025 results release and investor call with webcast details.

Pattern Detected

News tied to commercial or strategic progress (earnings, partnerships) previously showed mixed reactions, with positive fundamentals sometimes met by negative price moves, while many conference-related items saw modest to strong gains.

Recent Company History

Over the last six months, Biodesix issued several updates spanning conferences, earnings, and partnerships. The company reported stronger Q3 2025 revenue and raised full‑year guidance, yet the stock declined after that release. An expanded Bio‑Rad partnership for ddPCR assays also coincided with a notable drop. In contrast, prior conference-related announcements, including investor events and R&D roadmap presentations, often saw small to very strong gains. Today’s conference-focused data presentations extend this pattern of using scientific and investor venues to highlight the Nodify Lung® and ESR1 assay franchises.

Market Pulse Summary

This announcement highlights Biodesix’s strategy of showcasing its Nodify Lung® tests and an ultra-s...

Analysis

This announcement highlights Biodesix’s strategy of showcasing its Nodify Lung® tests and an ultra-sensitive ESR1 assay across major meetings, emphasizing early lung cancer detection and resistance monitoring in HR+/HER2- breast cancer. Recognition at ISPOR Europe 2025 underlines the economic burden of pulmonary nodules and follow-up gaps. Investors may watch how these data translate into test adoption, Development Services demand, and subsequent earnings updates, alongside future conference disclosures and regulatory filings.

Key Terms

biomarker, autoantibody, pulmonary nodule, droplet digital pcr, +4 more

8 terms

biomarker medical

"Post-Market Data from a Blood-based Biomarker Test in Pulmonary Nodule Patients."

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

autoantibody medical

"Impact of an Autoantibody Blood Test for Lung Cancer on Time to Diagnosis"

An autoantibody is a protein made by the immune system that mistakenly targets a person’s own cells or proteins, like a security guard that starts attacking the building it’s meant to protect. For investors, autoantibodies matter because they can be used as diagnostic markers, indicate safety issues for drugs, influence clinical trial outcomes and regulatory decisions, and therefore affect the market value of diagnostics and therapeutics companies.

pulmonary nodule medical

"Biomarker Test in Pulmonary Nodule Patients."

A pulmonary nodule is a small, round or oval spot seen on a lung scan, typically no larger than a cherry, that may be harmless or signal infection, inflammation, or a developing disease. For investors, nodules matter because they can lead to follow-up tests, treatments, or medical products and regulatory decisions that affect the revenue and valuation of healthcare companies tied to diagnostics, imaging, drugs or devices.

droplet digital pcr medical

"Development of an ultra-sensitive droplet digital PCR test for monitoring ESR1"

Droplet digital PCR is a laboratory method that splits a DNA or RNA sample into thousands of tiny droplets and runs many parallel tests so you can count exactly how many droplets contain the target genetic material. Like checking which bulbs in a giant string are lit, it gives a precise, highly sensitive measure of low-level DNA/RNA signals. Investors care because this accuracy enables better diagnostics, patient monitoring, and drug development decisions, and it supports sales of specialized instruments, assays, and recurring consumables.

liquid biopsies medical

"ESR1 variants in liquid biopsies.Authors: Leisa Jackson"

Liquid biopsies are non‑surgical tests that look for tiny pieces of tumor material, such as DNA or cells, circulating in body fluids (usually blood) to detect or monitor cancer. For investors, they matter because they offer faster, cheaper and less invasive ways to catch disease earlier and track treatment response, which can shift how diagnostics, drug trials and ongoing care are paid for and create sizable commercial opportunities — like a smoke detector sensing a fire without opening the walls.

esr1 medical

"ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring"

ESR1 is a gene that makes the estrogen receptor alpha protein, a cellular “lock” that the hormone estrogen (the “key”) fits into to tell cells how to grow, divide and behave. Mutations or changes in ESR1 can change how cancers—especially breast and other hormone-driven tumors—respond to hormone-blocking drugs, so investors track ESR1-linked tests, drugs and trial results because they directly affect treatment choices, market size and regulatory chances in oncology and women’s health.

hr+/her2- medical

"monitoring of the mutations in HR+/HER2- advanced breast cancers"

A cancer subtype where tumor cells have hormone receptors for estrogen and/or progesterone (HR+) but lack excess HER2 protein (HER2−). Think of receptors as locks: HR+ tumors have locks that can be targeted by hormone-blocking drugs, while HER2− means a different lock is absent, so HER2-targeted medicines won’t work. For investors this classification matters because it determines which therapies are appropriate, how large the patient market is, and which clinical trials and regulatory paths are relevant.

pharmacoeconomics medical

"International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025"

Pharmacoeconomics measures the value of a drug or medical treatment by comparing its costs (price, administration, side-effect management) to the health benefits it delivers (improved outcomes, fewer hospital visits). Like weighing the long‑term cost and performance of two cars, it helps payers and regulators decide which therapies to cover and at what price. Investors use pharmacoeconomic results to gauge likely reimbursement, market size, and revenue potential for healthcare products.

AI-generated analysis. Not financial advice.

Clinical utility data for Nodify Lung^® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer

Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS)

LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagnostics and new research on breast cancer diagnostics at upcoming scientific meetings.

At the 2025 North American Conference on Lung Cancer (NACLC), December 5 - 7, in Chicago, IL, Biodesix will present new findings on its on-market Nodify Lung^® tests, with data that spotlight the importance of timely, accurate lung nodule risk classification to support the early detection of lung cancer:

• Refining Post-test Probability of Lung Cancer Using Post-Market Data from a Blood-based Biomarker Test in Pulmonary Nodule Patients.
  Authors: Michael N. Kammer, PhD (Biodesix Head of Radiomics and Presenter); Trevor Pitcher, PhD; Gary Pestano, PhD; Laura Peek, PhD; James R. Jett, MD, MS, FCCP; Steven C. Springmeyer, MD, FCCP.

• Modeling the Impact of an Autoantibody Blood Test for Lung Cancer on Time to Diagnosis in Pulmonary Nodule Assessment: A Multi-Cohort Analysis.
  Authors: Kathryn Long, MD (Presenter); Gerard A. Silvestri, MD, MS, Master FCCP; Michael N. Kammer, PhD; Trevor Pitcher, PhD; James Jett, MD; Viswam S. Nair, MD.

The company will also present data on the development of a new ultra-sensitive ESR1 test for initial detection and monitoring of the mutations in HR+/HER2- advanced breast cancers at the San Antonio Breast Cancer Symposium, December 9 -12, San Antonio, TX. This innovative test is now available to biopharmaceutical customers as part of the company’s Development Services offering:

• Poster Session 4, PS4-02-29: Development of an ultra-sensitive droplet digital PCR test for monitoring ESR1 variants in liquid biopsies.
  Authors: Leisa Jackson (Biodesix Staff Scientist and Presenter), Helen Halpin, and Gary Pestano, PhD.

In addition, at the recent International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025 Meeting in November, Biodesix was awarded two distinguished recognitions: a Best General Poster Research Presentation and a Top 5% Research Certificate. The presented research highlighted the significant healthcare costs associated with pulmonary nodules and the widespread lack of appropriate follow-up. These gaps in nodule surveillance contribute to delayed diagnoses and increased downstream clinical and economic burden. ISPOR will publish all award-winning research in their December 2025 conference supplement issue of Value in Health.

• PT5: Pulmonary Nodule (PN)-Related and Lung Cancer-Related Workup Costs Within the Two-Year Period After Diagnosis of a PN in the United States
  Author: Kimberly Le, MBA, MS, PharmD (Biodesix Director of HEOR and Presenter).

About Biodesix:

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung^® Nodule Risk Assessment and IQLung^® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications, Biodesix
natalie.stdenis@biodesix.com
(720) 925-9285

Investors:
Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com
(339) 970-2843

FAQ

What data will Biodesix (BDSX) present at NACLC Dec 5–7, 2025?

Biodesix will present post‑market Nodify Lung® data on refining post‑test lung cancer probability and a multi‑cohort model of autoantibody testing impact on time to diagnosis.

When and where will Biodesix present the ultra‑sensitive ESR1 assay for breast cancer (BDSX)?

Biodesix will present the ESR1 droplet digital PCR development data at SABCS, Dec 9–12, 2025 in San Antonio, TX.

Is the new ultra‑sensitive ESR1 test from Biodesix available to customers (BDSX)?

Yes; the ESR1 assay is available to biopharmaceutical customers through Biodesix Development Services.

What recognitions did Biodesix (BDSX) receive at ISPOR Europe 2025?

Biodesix received a Best General Poster Research Presentation and a Top 5% Research Certificate for pulmonary nodule cost and follow‑up research.

How do the NACLC Nodify Lung® findings relate to lung cancer diagnosis timing (BDSX)?

The presented Nodify Lung® post‑market analyses focus on improving risk classification to support earlier detection and inform nodule follow‑up.